We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
An Updated Systematic and Comprehensive Review of Cytoreductive Prostatectomy for Metastatic Prostate Cancer.
- Authors
Yanagisawa, Takafumi; Rajwa, Pawel; Kawada, Tatsushi; Bekku, Kensuke; Laukhtina, Ekaterina; Deimling, Markus von; Majdoub, Muhammad; Chlosta, Marcin; Karakiewicz, Pierre I.; Heidenreich, Axel; Kimura, Takahiro; Shariat, Shahrokh F.
- Abstract
(1) Background: Local therapy is highly promising in a multimodal approach strategy for patients with low-volume metastatic prostate cancer (mPCa). We aimed to systematically assess and summarize the safety, oncologic, and functional outcomes of cytoreductive prostatectomy (cRP) in mPCa. (2) Methods: Three databases were queried in September 2022 for publications that analyzed mPCa patients treated with cytoreductive prostatectomy without restrictions. The outcomes of interest were progression-free survival (PFS), cancer-specific survival (CSS), overall survival (OS), perioperative complication rates, and functional outcomes following cRP. (3) Results: Overall, 26 studies were included in this systematic review. Among eight population-based studies, cRP was associated with a reduced risk of CSS and OS compared with no local therapy (NLT) after adjusting for the effects of possible confounders. Furthermore, one population-based study showed that cRP reduced the risk of CSS even when compared with radiotherapy (RT) of the prostate after adjusting for the effects of possible confounders. In addition, one randomized controlled trial (RCT) demonstrated that local therapy (comprising 85% of cRP) significantly improved the prostate-specific antigen (PSA)-PFS and OS. Overall, cRP had acceptable perioperative complication rates and functional outcomes. (4) Conclusions: Mounting evidence suggests that cRP offers promising oncological and functional outcomes and technical feasibility and that it is associated with limited complications. Well-designed RCTs that limit selection bias in patients treated with cRP are warranted.
- Subjects
PROSTATECTOMY; CYTOREDUCTIVE surgery; PROSTATE cancer treatment; SURGICAL complications; PROGRESSION-free survival
- Publication
Current Oncology, 2023, Vol 30, Issue 2, p2194
- ISSN
1198-0052
- Publication type
Article
- DOI
10.3390/curroncol30020170